4CPS-158 Prescribing trends of adalimumab and etanercept biosimilar drugs in a third level hospital
| Autor: | T Salvador Gómez, R Fresquet Molina, O Horna Oreja, MA Alcácera López, M Gimeno Gracia, JM Vinuesa Hernando, A Frutos Perez-Surio, R Gracia Piquer, FJ Campos Montellano, M Galindo Allueva |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty business.industry Spondyloarthropathy Biosimilar medicine.disease Inflammatory bowel disease Etanercept Psoriatic arthritis Rheumatoid arthritis Psoriasis Internal medicine medicine Adalimumab skin and connective tissue diseases business medicine.drug |
| Zdroj: | Section 4: Clinical Pharmacy Services. |
| DOI: | 10.1136/ejhpharm-2020-eahpconf.259 |
| Popis: | Background and importance Adalimumab and etanercept are two of the most used biologic drugs worldwide in a variety of chronic diseases. The introduction of biosimilar drugs (BS) for both has revolutionised the market and may enable more patients to access these treatments. Aim and objectives To measure the use of etanercept and adalimumab biosimilars since their introduction in a third level hospital. Material and methods We studied the number of patients treated with biological reference products (BRP) and with their corresponding biosimilars since the introduction of etanercept (April 2018) and adalimumab BS (January 2019) in our hospital until September 2019. The results were analysed with Excel. Results There were 211 patients treated with etanercept, 36.7% for spondyloarthropathy, 35.1% for rheumatoid arthritis, 14.8% for psoriatic arthritis and 13.4% for psoriasis. In 41.7% of patients, treatment was with a BS the, 38.4% as a new treatment and 3.3% as a switch. Of the 3.3% who switched, 43% were patients with psoriasis, 29% with psoriatic arthritis, 14% with rheumatoid arthritis and 14% with spondyloarthropathy. We found that 4.9% of the total number of patients started with the BRP. We identified 452 patients being treated with adalimumab, 46.2% for arthropathies, 31.0% for inflammatory bowel disease, 16.4% for psoriasis and 6.4% for other diseases. In 18.9% of patients, treatment was with a BS, 17.0% in new patients and 1.9% as a switch. Every switch was done in psoriatic patients. We found that 1.3% of the total number of patients started treatment with the BRP. Conclusion and relevance The use of the biosimilars of etanercept and adalimumab was highly accepted when initiating a new treatment and switching is starting to increase, especially in psoriasis. It is important to design a strategy that could enhance switching from the BRP to the biosimilar drug in pathologies other than psoriasis where patients have chronic conditions and will need treatment for a long period of time. References and/or acknowledgements http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.508 No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|